The Clinical Impact of [68Ga]‐DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours

Volume: 91, Issue: 2, Pages: 288 - 294
Published: Jun 12, 2019
Abstract
Objectives Localization of ectopic ACTH‐secreting tumours causing Cushing syndrome (ECS) is essential for clinical management, yet often difficult. [ 68 Ga]‐DOTATATE PET/CT ([ 68 Ga]‐DOTA‐(Tyr 3 )‐octreotate)] is an FDA‐approved high‐resolution diagnostic tool for imaging neuroendocrine tumours. Data on the clinical utility of [ 68 Ga]‐DOTATATE in patients with ECS, however, are scarce. The objectives of this study were to determine the efficacy...
Paper Details
Title
The Clinical Impact of [68Ga]‐DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours
Published Date
Jun 12, 2019
Volume
91
Issue
2
Pages
288 - 294
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.